Senna alexandrina

Senna alexandrina is a medicinal plant whose primary bioactive compounds, sennosides A and B, act as stimulant laxatives by being converted by colonic bacteria into rheinanthrone, which irritates the intestinal mucosa and increases colonic motility. It is clinically validated for relieving occasional constipation and for bowel preparation prior to colonoscopy procedures.

Origin & History

Senna alexandrina is a plant species in the Fabaceae family, native to North Africa (Egypt, Sudan) and widely cultivated in India. The dried leaflets (folium) or fruits (fructus) are processed into standardized extracts, tinctures, fluid extracts, decoctions, or infusions containing hydroxyanthracene derivatives (anthraquinone glycosides).

Historical & Cultural Context

Senna has been used for centuries in traditional herbal medicine systems, particularly Western/European herbalism and African/Arabic traditions, as a stimulant laxative. WHO monographs document its use in global traditional medicine spanning over 1,000 years, including ancient Egyptian and Indian systems.

Health Benefits

• Relieves constipation through stimulant laxative action - supported by clinical trials including postpartum study (Shelton, 1980) showing significant improvement without habituation
• Effective for bowel preparation before colonoscopy - RCT by Vradelis et al. (2009) showed improved cleansing quality when combined with magnesium citrate
• Comparable to PEG-EL for colonoscopy preparation - Altinbaş et al. (2015) RCT demonstrated similar cleansing efficacy
• Short-term management of occasional constipation - WHO monographs (1999) document supportive evidence for this traditional use
• Postpartum constipation relief - randomized trial in 40 women demonstrated effectiveness versus placebo

How It Works

Sennosides A and B in senna are prodrugs metabolized by colonic microflora into the active metabolite rheinanthrone, which stimulates afferent nerve endings in the colonic mucosa to increase peristaltic contractions via prostaglandin-mediated pathways. Rheinanthrone also inhibits Na+/K+-ATPase activity in colonocytes, reducing electrolyte and water reabsorption and increasing luminal fluid content. This dual action—enhanced motility and increased intraluminal water—produces a laxative effect typically within 6 to 12 hours of oral administration.

Scientific Research

Clinical evidence includes an RCT by Shelton (1980) in 40 postpartum women showing senna's effectiveness for constipation relief. Vradelis et al. (2009, PMID: 19399979) studied 200 patients comparing magnesium citrate plus senna versus magnesium citrate alone for colonoscopy preparation, finding improved bowel cleansing. Altinbaş et al. (2015, PMID: 26172339) compared sennoside-based regimen to PEG-EL in 198 patients, showing comparable efficacy.

Clinical Summary

A 1980 RCT by Shelton involving postpartum women demonstrated that senna produced statistically significant improvement in bowel movement frequency compared to placebo, with no evidence of habituation over the study period. A 2009 RCT by Vradelis et al. found that senna-based bowel preparation achieved superior colon cleansing quality scores compared to standard polyethylene glycol regimens in patients undergoing colonoscopy. The EMA has granted senna a well-established use monograph for short-term treatment of occasional constipation, supported by decades of pharmacological and clinical data. Evidence quality is moderate; most trials are short-term, and long-term efficacy and safety data beyond several weeks remain limited.

Nutritional Profile

Senna alexandrina (Alexandrian senna) is a medicinal plant, not a food ingredient, so it lacks significant macronutrient or caloric value in therapeutic doses. Key bioactive compounds include: Anthraquinone glycosides (sennosides A and B as primary actives, comprising 1.5–3% of dried leaf weight; standardized commercial preparations typically contain 13.5–54 mg sennosides per dose); sennosides C and D present in smaller concentrations (~0.1–0.3%); free anthraquinones including rhein, aloe-emodin, and chrysophanol (0.05–0.2% in dried leaf). Naphthalene glycosides (tinnevellin glycoside) found predominantly in Tinnevelly-type senna pods. Flavonoids include kaempferol, isorhamnetin, and their glycosides (~0.5–1.2% of dry weight). Mucilaginous polysaccharides present in pods (~5–10% dry weight), contributing minor fiber content. Resin components (~1% dry weight). Calcium, potassium, and magnesium present in trace amounts typical of dried plant material (calcium ~500–800 mg/100g dry leaf; potassium ~900–1200 mg/100g). Protein content negligible (<2% dry weight). Bioavailability note: Sennosides A and B are prodrugs, poorly absorbed in the upper GI tract; they are hydrolyzed by colonic bacteria into active rhein anthrone, which exerts local laxative effect — systemic absorption is minimal, limiting systemic nutritional contribution.

Preparation & Dosage

Clinically studied dosages standardize to 15-30 mg sennoside B (hydroxyanthracene derivatives calculated as sennoside B) per day for adults. Take 2-3 times weekly, increasing to once daily if needed, ideally at bedtime allowing 6-12 hours for effect. Available as dry extracts, tinctures, fluid extracts, decoctions, or infusions. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Magnesium citrate, Psyllium husk, Probiotics, Aloe vera, Cascara sagrada

Safety & Interactions

Short-term use of senna is generally well tolerated, but common side effects include abdominal cramping, diarrhea, and electrolyte imbalances, particularly hypokalemia with prolonged use, which can potentiate cardiac glycosides such as digoxin and increase risk of arrhythmia. Chronic use beyond 1–2 weeks may cause laxative dependency, melanosis coli (a reversible discoloration of the colon), and atonic colon. Senna is contraindicated in intestinal obstruction, inflammatory bowel disease, appendicitis, and severe dehydration, and should be avoided during pregnancy beyond the first trimester and in children under 12 years without medical supervision. Concomitant use with diuretics or corticosteroids amplifies the risk of electrolyte depletion and requires clinical monitoring.